Morepen Labs net profit leaps over 6 fold to Rs 27crore in Q2

Published On 2020-11-11 06:35 GMT   |   Update On 2020-11-11 06:35 GMT

New Delhi: Drug firm Dr Morepen Laboratories on Monday reported an over six-fold jump in its consolidated net profit to Rs 27.16 crore for the quarter ended September, on account of robust sales. The company had posted a net profit of Rs 4.08 crore for the corresponding period of the previous fiscal, Morepen Labs said in a BSE filing.Total revenue stood at Rs 340.12 crore for the quarter...

Login or Register to read the full article

New Delhi: Drug firm Dr Morepen Laboratories on Monday reported an over six-fold jump in its consolidated net profit to Rs 27.16 crore for the quarter ended September, on account of robust sales. The company had posted a net profit of Rs 4.08 crore for the corresponding period of the previous fiscal, Morepen Labs said in a BSE filing.

Total revenue stood at Rs 340.12 crore for the quarter under consideration. It was Rs 216.24 crore for the same period a year ago, it added.
"Company is investing heavily to build strong pipeline of products to be launched in three to four years. This investment would go both in R&D and in building new product blocks to create extra production capacities," Morepen Laboratories Chairman and MD Sushil Suri said.
The focus of the company continues to remain on the chronic and lifestyle diseases, he added.

Read also: Morepen Labs net profit leaps over two-fold to Rs 19.36 crore in Q1



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News